With a population of almost 1 billion people, in an accelerated aging process and with a significant increase in access to health care services, Latin America has shown itself to be, in the last decades, an important market, becoming one of the biggest growth opportunities for the pharmaceutical industry in the world.
“LATIN AMERICA GREW TWICE AS MUCH AS THE GLOBAL DRUG MARKET IN 2020. THE MARKET HAS THE LARGEST GROWTH OPPORTUNITY IN THE PHARMACEUTICAL INDUSTRY IN THE WORLD.”
Says Latam Vice-President & Board Member at Close-Up International, Paulo Paiva.*
In Brazil, healthcare is a constitutional right for all and a duty of the State, so the Union, States, and Municipalities are responsible for the health of Brazilian citizens.
To fulfill its attributions, the structure of the Ministry of Health in Brazil is composed of secretariats, which are responsible for elaborating, proposing, and implementing health policies, and are the executors of the Ministry’s activities.
The SUS is the only public healthcare system in the world that serves more than 190 million people, 80% of whom depend exclusively on it for any healthcare.*
Brazil stands out in the global pharmaceutical panorama, currently oscillating between the 6th and 7th position. At this rate of growth, It is estimated that the country will reach 5th position in 2023*.
ACCORDING TO DATA FROM THE MINISTRY OF HEALTH, ABOUT 13 MILLION BRAZILIANS ARE CARRIERS OF SOME RARE DISEASE.
Besides these facts, Brazil increased 43.3% in its Expenditure Current Health Care per Capita in PPP*, being at the same level as the OECD and approaching countries such as Germany, France, Canada, and Japan.
Health expenditure as a proportion of GDP, by institutional sector (%) in 2017.**
** IBGE compared private and public spending on health in several countries and found that, in Brazil, families spend more and the government spends less than the average. Photo: reprocution / IBGE
For Multicare, enabling access to life-saving medicines can make the future possible for millions of people.
Contact us, learn about our services and how we can help in the expansion of treatments for rare and highly complex diseases in Brazil and Latin America.
We are the best option for access to medicines for the treatment of rare or highly complex diseases. We have been present in the pharmaceutical market for 37 years and have become a reference in the area of rare and highly complex diseases in the last decade.
Talk to us: firstname.lastname@example.org
Learn more: www.multicarepharma.com